{
    "Trade/Device Name(s)": [
        "Atellica\u00ae CH Creatinine_3 (Crea3)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K242685",
    "Predicate Device Reference 510(k) Number(s)": [
        "K161494"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGX"
    ],
    "Summary Letter Date": "December 4, 2024",
    "Summary Letter Received Date": "September 6, 2024",
    "Submission Date": "September 6, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin, dipotassium EDTA, sodium heparin)",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae CH Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Alkaline picrate colorimetry",
        "Modification of Jaffe method",
        "Rate blanking and intercept correction"
    ],
    "Methodologies": [
        "Colorimetry"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Atellica CH Creatinine_3 (Crea3) assay for quantitative creatinine determination using Atellica CH Analyzer",
    "Indications for Use Summary": "For quantitative determination of creatinine in human serum, plasma (lithium heparin, dipotassium EDTA, and sodium heparin), and urine to aid in diagnosis and treatment of renal diseases and monitoring renal dialysis",
    "fda_folder": "Clinical Chemistry"
}